Nama's AI scorecard currently rates Arrowhead Pharmaceuticals Sell (1.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ARWR report earnings?

Arrowhead Pharmaceuticals's next scheduled report is on Nov 24, 2026. Analysts expect EPS of -$1.50.

What is the ARWR price target?

The median analyst price target from 14 analysts is $106.50, with a range of $74.00 – $126.00.

Is ARWR Shariah compliant?

Nama's AAOIFI-style screen reads Arrowhead Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Arrowhead Pharmaceuticals (ARWR)

Healthcare · Biotechnology · NASDAQ

Arrowhead Pharmaceuticals (ARWR) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $8.22B and a free-cash-flow yield of 2.0%. Over the most recent reported fiscal year, revenue grew 23258.2%. Nama's AI scorecard rates it Sell, 1.6 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 1.6/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Rising · +55.2% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-39.1%

How far the last close sits under the highest price of the past five years.

Market cap	$8.22B
Trailing P/E	—
Price / book	17.6
Price / sales	12.3
FCF yield	2.0%
Dividend yield	—
Gross margin	100.0%
Operating margin	-226.0%
Net margin	-47.8%
Revenue growth (YoY)	+23258.2%
Revenue growth (3-yr annual)	+50.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ARWR earnings

Next report: Nov 24, 2026 (Q4 2026, EPS estimate -$1.50). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Aug 4, 2026	-$1.36	-$1.23	-10.6%	$75.25M
Q2 2026	May 7, 2026	-$0.93	-$1.11	+16.2%	$73.74M
Q1 2026	Feb 5, 2026	$0.22	-$0.37	+159.5%	$264.03M
Q4 2025	Nov 25, 2025	-$0.18	-$0.16	-12.5%	$256.47M

ARWR analyst price target

Median target $106.50 from 14 analysts, ranging $74.00 – $126.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ARWR data on Nama Insights →

ARWR FAQ

Is ARWR a buy?: Nama's AI scorecard currently rates Arrowhead Pharmaceuticals Sell (1.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ARWR report earnings?: Arrowhead Pharmaceuticals's next scheduled report is on Nov 24, 2026. Analysts expect EPS of -$1.50.
What is the ARWR price target?: The median analyst price target from 14 analysts is $106.50, with a range of $74.00 – $126.00.
Is ARWR Shariah compliant?: Nama's AAOIFI-style screen reads Arrowhead Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.